Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts SNSS Hot Sheet
Price: $5.32 --0%
Financial Fact:
Total operating expenses: 10.6M
Today's EPS Names:
QEPC, NTRP, LOOP, More
Financial Fact:
Total operating expenses: 10.6M
Today's EPS Names:
QEPC, NTRP, LOOP, More
Join SI Premium – FREE
Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $600 thousand.
For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Prologis (PLD) Tops Q3 EPS by 8c; revises guidance
- Slew of analyst comments sends Take-Two (TTWO) up 4% ahead of November earnings and GTV 6
- Alcoa (AA) Tops Q3 EPS by 28c, Misses on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
